Skip to content

Medicortex Finland is dedicated to improving the diagnostics, treatment and prevention of acute neurodegenerative conditions. Current focus is on developing a novel biomarker based diagnostic test for traumatic brain injuries (TBI). After the development project the company will focus on a multiplex treatment for TBI.

Management Team

The Management Team consists of the CEO and other members appointed by the Board of Directors. Our capable management team consists of four people, the CEO, CSO, COO, and CFO.

Dr. Adrian Harel

Chief Executive Officer (CEO), Founder of Medicortex, and Board member

Chief Executive Officer since: 2014

About: Dr. Harel, has a PhD in Neurobiology, from the Weizmann Institute of Science, and was a postdoctoral at Washington University. He has many years of experience in the pharmaceutical and biotech industry. Dr. Harel has extensive Drug R&D know-how and GMP production and manufacturing knowledge. He combines a broad scientific education with extensive industry experience. See more at ’Board of Directors’.

Dr. Lasse Välimaa

Chief Scientific Officer (CSO)

Chief Scientific Officer since: 2021 (before that: ’Head of R&D’ since 2015)

About: Dr. Välimaa, the head of R&D since 2015, has a PhD in Molecular Biotechnology and Diagnostics at the University of Turku, Finland. His background is in the R&D of bioanalytical methods and medical diagnostics. Dr. Välimaa has diagnostic assay development practical experience, as well as analytical and biochemical knowledge and hands-on experience. At Medicortex, Dr. Välimaa is involved in a wide range of study activities, covering, inter alia, clinical protocol preparation, sample analysis management, results analysis and development of detection methods. His role will range from supervising and coordinating study activities to hands-on work with samples and laboratory experiments. In his previous academic positions as a Researcher and Project Manager, he addressed several technical features influencing the performance of biochemical binding assays.

Pihla Miettinen

Chief Operating Officer (COO)

Chief Operating Officer since: 2023 (before that: ’Research Coordinator’ since 2022)

About: Pihla Miettinen has a MSc degree in Human Neuroscience at the University of Turku, Finland. She has been operating as the COO at Medicortex since 2023, before which she acted as the Research Coordinator since 2022. Ms. Miettinen has practical experience and scientific know-how in molecular and cellular neurosciences as well as clinical neuroscience. At Medicortex, Ms. Miettinen is responsible for a variety of tasks including purchases, import, and finding suppliers, as well as human resources and public relations. In her previous position, she was conducting research into the inhibition of tau aggregation in mice neuronal cells.

Tommi Merla

Chief Financial Officer (CFO)

Chief Financial Officer since: 2024

About: Tommi Merla has a MSc degree in Economics (Finance) at the University of Turku, Finland. Merla is an experienced financial administration and business development professional. He has comprehensive range of skills in business and financial management, accounting, and taxation, having worked in large multi-national corporations and start-up companies, in both consumer business and B2B.